Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, Barclays Analyst Says

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective lifted by Barclays from $42.00 to $47.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 13.24% from the company’s current price.

A number of other equities analysts have also recently issued reports on the company. Leerink Partners started coverage on Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock. TD Cowen started coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, October 1st. They set a “buy” rating and a $55.00 price target for the company. Piper Sandler boosted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Oppenheimer started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price objective on the stock. Twelve analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.92.

Teva Pharmaceutical Industries Trading Up 1.9%

NYSE:TEVA traded up $0.79 during mid-day trading on Thursday, hitting $41.51. 937,432 shares of the company’s stock were exchanged, compared to its average volume of 6,804,032. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries has a fifty-two week low of $18.83 and a fifty-two week high of $42.02. The company has a 50 day simple moving average of $38.03 and a 200-day simple moving average of $34.76. The firm has a market capitalization of $48.37 billion, a P/E ratio of 69.03, a PEG ratio of 3.83 and a beta of 0.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. The company had revenue of $4.14 billion during the quarter. As a group, research analysts expect that Teva Pharmaceutical Industries will post 2.00 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares of the company’s stock, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 374,959 shares of company stock worth $14,644,285. Company insiders own 0.54% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several large investors have recently modified their holdings of TEVA. Cornerstone Planning Group LLC grew its holdings in Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after purchasing an additional 755 shares during the period. Western Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at $43,000. Sunbelt Securities Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at $45,000. CX Institutional bought a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at $54,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after buying an additional 647 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.

Teva’s portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia.